You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long non coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases

    SBC: IQuity Labs, Inc.            Topic: NIAID

    No other group of diseases encompasses a greater pathophysiology than do the rheumatic diseases Spanning multiple organ systems clinical decisions often rely on coordinated efforts from primary care providers and rheumatologists to rule in or rule out differential diagnoses when treating inflammatory conditions such as rheumatoid arthritis RA and systemic lupus erythematosus SLE RA is a sym ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Developing specific rapid and cost effective immunoassays for Zika detection

    SBC: MEDIOMICS, LLC            Topic: R

    This proposal aims to develop highly specific rapid and cost effective immunoassays to detect Zika virus ZIKV infection ZIKV is a single stranded RNA virus in the Flaviviridae family that is transmitted to humans through infected mosquitos blood transfusions and sexual contact As of June around Zika Virus disease cases have been estimated in Brazil alone Recently ZIKV has be ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting the alternative pathway to treat age related macular degeneration

    SBC: Serion, Inc            Topic: N

    Targeting the alternative pathway of complement to treat age related macular degeneration Abstract Age related macular degeneration AMD is the leading cause of vision loss in the developed world in people over and is a priority research area for the National Eye Institute It is a progressive degenerative disease that causes loss of the central vision due to destruction of the part of the re ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. The Preemie Pacer An Innovative Bottle to Promote Safe and Efficient Oral Feeding in Preterm Infants

    SBC: PREEMIE-PACER LLC            Topic: NICHD

    PROJECT SUMMARY ABSTRACT There are infants born preterm each year in the United States alone Preterm infants often necessitate care in the neonatal intensive care unit One of the final milestones to be achieved in order to be discharged from the neonatal intensive care unit is oral feeding Oral feeding can be a challenge for infants born preterm as they do not have the maturity that all ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    Overmillion women suffer from urinary tract infectionsUTIannually in the U Sandof these patients will suffer from recurrent infectionsincluding approximatelypatientsmostly womenwho will suffer from highly recurrentgreater thanepisodes per yearUTIAntimicrobial treatment of UTIs has resulted in increasing antimicrobial resistance among uropathogenic EcoliUPECto first line empiric therapiessuch as tr ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. ITK TXK Inhibitors as Oral Immunotherapeutic Drugs for Psoriasis

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NIAMS

    Psoriasis is a devastating autoimmune disease that manifests itself in the form of patchy inflammatory skin lesions that can appear anywhere throughout the body resulting in tremendous physical pain and discomfort This chronic disease can also cause arthritic joints and have a profound impact on a patient s psychological well being In psoriatic lesions the detection of increased numbers of T c ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. HLS Potent novel inhibitor of fibrinolytic hemorrhage

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest therapeutics that are of high programmatic interest HL Hemorrhage or bleeding is a serious or fatal complication of surgery Antifibrinolytic agents that inhibit plasmin mediated fibrinolysis can significantly reduce blood loss emergency reoperation morbidity and death in patients with severe hemor ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government